Other Consolidated Financial Statement Detail (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Other Income (Expense), Net
Interest income	$ 5,900,000	$ 5,300,000	$ 22,600,000	$ 13,300,000
Interest expense	(8,700,000)	(7,900,000)	(23,100,000)	(25,500,000)
Impairment of investments	(3,500,000)	(800,000)	(4,800,000)	(7,600,000)
Gain (loss) on sales of investments, net	1,300,000	(100,000)	15,600,000	15,400,000
Foreign exchange gains (losses), net	100,000	(4,800,000)	200,000	(5,800,000)
Other, net	400,000	600,000	3,100,000	700,000
Total other income (expense), net	(4,548,000)	(7,727,000)	13,546,000	(9,504,000)
Accrued Expenses and Other
Employee compensation and benefits	198,700,000		198,700,000		176,300,000
Revenue-related rebates	160,200,000		160,200,000		115,000,000
Deferred revenue	140,600,000		140,600,000		69,600,000
Collaboration expenses	46,600,000		46,600,000		44,200,000
Clinical development expenses	52,900,000		52,900,000		40,800,000
Royalties and licensing fees	45,300,000		45,300,000		47,400,000
Current portion of contingent consideration obligations	21,300,000		21,300,000		10,800,000
Other	200,600,000		200,600,000		173,100,000
Total accrued expenses and other	$ 866,208,000		$ 866,208,000		$ 677,210,000